Update and review of central retinal vein occlusion

Curr Opin Ophthalmol. 2011 May;22(3):159-65. doi: 10.1097/ICU.0b013e3283459737.


Purpose of review: To review the clinical picture of central retinal vein occlusion (CRVO), with an emphasis on recent therapeutic developments.

Recent findings: The most significant advances with regard to CRVO relate to the establishment of the important role of intravitreal anti-vascular endothelial growth factor and corticosteroids in the treatment of macular edema associated with vein occlusion.

Summary: Important objectives on evaluation of a patient presenting with a CRVO include differentiation between ischemic and nonischemic types, identification of any complications, and establishment of a treatment and/or follow-up plan. Macular edema is one of the main causes of vision loss in CRVO, and for the first time we can have effective treatment options for affected patients.

Publication types

  • Review

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use
  • Glucocorticoids / therapeutic use
  • Humans
  • Intravitreal Injections
  • Macular Edema / drug therapy
  • Retinal Vein Occlusion / drug therapy*
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors


  • Angiogenesis Inhibitors
  • Glucocorticoids
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A